title: Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
abstract: The plant alkaloid galantamine is an established symptomatic drug treatment for Alzheimer's disease (AD), providing temporary cognitive and global relief in human patients. In this study, the 5X Familial Alzheimer's Disease (5XFAD) mouse model was used to investigate the effect of chronic galantamine treatment on behavior and amyloid β (Aβ) plaque deposition in the mouse brain. Quantification of plaques in untreated 5XFAD mice showed a gender specific phenotype; the plaque density increased steadily reaching saturation in males after 10 months of age, whereas in females the density further increased until after 14 months of age. Moreover, females consistently displayed a higher plaque density in comparison to males of the same age. Chronic oral treatment with galantamine resulted in improved performance in behavioral tests, such as open field and light-dark avoidance, already at mildly affected stages compared to untreated controls. Treated animals of both sexes showed significantly lower plaque density in the brain, i.e., the entorhinal cortex and hippocampus, gliosis being always positively correlated to plaque load. A high dose treatment with a daily uptake of 26 mg/kg body weight was tolerated well and produced significantly larger positive effects than a lower dose treatment (14 mg/kg body weight) in terms of plaque density and behavior. These results strongly support that galantamine, in addition to improving cognitive and behavioral symptoms in AD, may have disease-modifying and neuroprotective properties, as is indicated by delayed Aβ plaque formation and reduced gliosis.
authors.affiliation: Neurogenetics Special Laboratory, Leibniz Institute for Neurobiology, Magdeburg, Germany.
authors.forename: Soumee
authors.initials: S
authors.lastname: Bhattacharya
authors.affiliation: Neurogenetics Special Laboratory, Leibniz Institute for Neurobiology, Magdeburg, Germany.
authors.forename: Christin
authors.initials: C
authors.lastname: Haertel
authors.affiliation: Galantos Pharma GmbH, Nieder-Olm, Germany.
authors.forename: Alfred
authors.initials: A
authors.lastname: Maelicke
authors.affiliation: Neurogenetics Special Laboratory, Leibniz Institute for Neurobiology, Magdeburg, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Montag
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D005702:Galantamine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D051379:Mice; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D058225:Plaque, Amyloid / Q000188:drug therapy* / Q000473:pathology; D012737:Sex Factors
chemical_list: D002800:Cholinesterase Inhibitors; D005702:Galantamine